Aaron K. Grant1, Elena Vinogradov2, Xiaoen Wang1, Rupal Bhatt3, Robert E. Lenkinski2, David C. Alsop1
1Department of Radiology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, United States; 2Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX; 3Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, United States
Anti-angiogenic therapies can dramatically reduce tumor perfusion and vascular permeability. Here we present the use of hyperpolarized 13C labeled tert-butanol for monitoring changes in tumor perfusion resulting from anti-angiogenic therapy in a model of renal cell carcinoma. Dynamic imaging of with balanced SSFP enables quantification of the reduction in blood flow following treatment. In addition, metabolic imaging was performed with hyperpolarized pyruvate to assess changes in metabolism. In a small pilot study, imaging with tert-butanol indicates reductions in blood flow on the order of 70%, while the change in lactate signal following treatment shows more variability.